Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $73,458.00 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Ventures L.P. 5Am sold 10,494 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $7.00, for a total transaction of $73,458.00. Following the transaction, the insider owned 2,836,098 shares in the company, valued at approximately $19,852,686. The trade was a 0.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Entrada Therapeutics Stock Up 8.9%

Entrada Therapeutics stock opened at $7.67 on Thursday. The stock has a market cap of $298.67 million, a price-to-earnings ratio of -1.94 and a beta of -0.26. Entrada Therapeutics, Inc. has a 12 month low of $5.02 and a 12 month high of $16.45. The business has a 50 day moving average price of $6.89 and a two-hundred day moving average price of $9.62.

Entrada Therapeutics (NASDAQ:TRDA) last issued its earnings results on Wednesday, August 5th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The firm had revenue of $0.90 million during the quarter, compared to analyst estimates of $2.32 million. Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. On average, analysts expect that Entrada Therapeutics, Inc. will post -4.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on TRDA. Weiss Ratings cut shares of Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday, June 11th. Roth Capital restated a “buy” rating and set a $11.00 target price on shares of Entrada Therapeutics in a research report on Wednesday. HC Wainwright downgraded shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. Finally, Guggenheim cut their target price on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Monday, June 8th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $17.75.

Institutional Trading of Entrada Therapeutics

A number of large investors have recently added to or reduced their stakes in TRDA. Geode Capital Management LLC raised its position in shares of Entrada Therapeutics by 7.2% in the second quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock valued at $4,245,000 after purchasing an additional 42,479 shares during the period. Rhumbline Advisers raised its position in shares of Entrada Therapeutics by 8.3% in the second quarter. Rhumbline Advisers now owns 39,095 shares of the company’s stock valued at $263,000 after buying an additional 2,982 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Entrada Therapeutics by 10.8% during the 2nd quarter. American Century Companies Inc. now owns 75,094 shares of the company’s stock valued at $505,000 after acquiring an additional 7,301 shares during the period. Prudential Financial Inc. lifted its position in Entrada Therapeutics by 23.4% during the second quarter. Prudential Financial Inc. now owns 28,340 shares of the company’s stock worth $190,000 after purchasing an additional 5,370 shares during the period. Finally, Invesco Ltd. lifted its holdings in shares of Entrada Therapeutics by 34.2% during the 2nd quarter. Invesco Ltd. now owns 22,393 shares of the company’s stock worth $150,000 after acquiring an additional 5,702 shares during the period. Institutional investors and hedge funds own 86.39% of the company’s stock.

Entrada Therapeutics News Summary

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $4.19 from $4.33 and its FY2027 estimate to a loss of $3.13 from $3.14. The improved longer-term forecasts may be helping sentiment, although the firm maintained a Neutral rating.
• Neutral Sentiment: HC Wainwright slightly worsened its estimates for the third and fourth quarters of 2026, forecasting losses of $1.18 and $1.04 per share, respectively. The revisions suggest continued heavy spending and ongoing losses, with the firm’s full-year FY2026 estimate still below the current consensus loss estimate of $4.07 per share.
• Neutral Sentiment: Institutional ownership remains high at approximately 86.4%. BlackRock established a new position, while Millennium Management, Citadel Advisors and Qube Research increased their holdings. These institutional purchases may provide some support, although the reported transaction periods are inconsistent and should be interpreted cautiously.
• Negative Sentiment: Major shareholder Ventures V. L.P. 5Am sold 62,811 shares for approximately $431,829 across August 6 and 7. Director Kush Parmar also sold 155,255 shares for roughly $1.08 million from August 6 through 10. The sales reduced their respective holdings but did not represent complete exits, as both continued to own substantial positions. SEC insider transaction filings
• Negative Sentiment: Entrada’s latest quarterly results were weaker than expected: the company reported a $1.01-per-share loss versus the $0.97 consensus estimate and revenue of $0.90 million versus expectations of $2.32 million. As a clinical-stage biotechnology company, TRDA remains dependent on pipeline progress and future financing rather than current operating profits.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.